Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, general and administrative expenses

Restructuring and employee severance

Amortization and other acquisition-related costs

Impairments and (gain)/loss on disposal of assets, net

Litigation (recoveries)/charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cardinal Health

Cordis develops and manufactures medical devices for diagnostics and interventional procedures to treat patients suffering from coronary and peripheral vascular diseases.On October 4, 2015, Cardinal Health announced that it has completed the acquisition of Johnson & Johnson's Cordis business for $1.944 billion.

Cordis

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Cardinal Health reports strong Q3 results, focuses on Pharma growth

Cardinal Health's Q3 results demonstrated strong performance in the Pharma segment, while the Medical segment faced challenges. The company raised its guidance for the year and emphasized the importance of Red Oak Sourcing in maintaining market dynamics. Looking ahead, the company is focused on executing its medical improvement plan and maximizing shareholder value.

Cardinal Health reports stable Q2 growth, eyes Pharma segment

Cardinal Health's Q2 2023 performance showcased stability and growth in the Pharma segment, with a return to profitability in the Medical segment.
The company's strategic focus on executing key priorities and driving shareholder value creation is evident in its financial results.
Challenges such as international freight costs and supply chain headwinds are being addressed, while opportunities in COVID therapies, pricing strategy, and growth investments are being pursued.
Overall, Cardinal Health's revised outlook and strong performance in key segments position it for continued growth and financial success.

Cardinal Health reports robust Q3 earnings, eyes biosimilars for growth

Cardinal Health delivered strong financial performance in Q3 2023, driven by robust growth in the Pharma segment.
While facing challenges in the Medical segment, the company remains focused on mitigating inflation and maximizing shareholder value.
With a positive outlook on future growth opportunities, Cardinal Health aims to address cost pressures and drive profitability.

Cardinal Health achieves record results, raises guidance for fiscal '24

Cardinal Health's strong performance in Q4 and fiscal year 2023, coupled with strategic initiatives and guidance raise, position the company for continued growth and success.
Challenges such as inflation mitigation and cost pressures are being addressed, while opportunities in organic growth and strategic investments pave the way for future profitability.
The company's focus on advancing Pharma, executing the Medical Improvement Plan, and maximizing shareholder value creation underscores its commitment to sustained growth and value creation.

Cardinal Health reports strong Q1 earnings, raises guidance for FY24

Cardinal Health's Q1 2024 earnings call showcased robust performance, with profit growth in both Pharma and Medical segments. The company raised EPS guidance, demonstrated strong cash flow generation, and emphasized customer service and shareholder value creation. Challenges include managing margins, nonoperating items, and commodity price impacts, while opportunities lie in healthcare sector growth, innovation, and market dynamics.

Cardinal Health reports robust Q2 earnings, raises EPS guidance

Cardinal Health's Q2 performance reflects strong revenue growth, improved cash flow, and raised EPS guidance, supported by strategic acquisitions and growth initiatives.
While facing challenges from nonrecurring adjustments and SG&A growth, the company remains focused on core businesses and driving future growth opportunities.
With a positive outlook on market-driven growth, cost management, and strategic priorities, Cardinal Health aims to sustain its momentum and deliver value to shareholders.

Cardinal Health reports robust Q3 earnings, eyes growth opportunities ahead

Cardinal Health's Q3 performance reflects strong financial results and strategic progress across key segments, with raised guidance for fiscal '24 and '25.
The company faces challenges such as managing customer transitions and inflationary impacts but is well-positioned to capitalize on growth opportunities.
By focusing on cost optimization, strategic partnerships, and customer-centric solutions, Cardinal Health aims to drive sustained growth and profitability.
Investments in technology, brand growth, and operational efficiency underscore Cardinal Health's commitment to delivering value to shareholders and customers.

Cardinal Health excels in fiscal '24, raises guidance for '25

Cardinal Health's strong performance in fiscal year '24, highlighted by record financial results and strategic progress, positions the company for continued success.
Despite challenges such as market dynamics and customer transitions, the company's raised guidance for fiscal year '25 underscores confidence in future growth.
By capitalizing on strengths like revenue growth in key segments and making strategic investments, Cardinal Health is poised to navigate challenges and seize opportunities for sustained growth.

Cardinal Health reports strong Q1 performance and raises fiscal guidance

Cardinal Health's Q1 performance showed strength in Pharma and Specialty Solutions despite revenue decrease.
Challenges in GMPD segment and nuclear supply disruptions are being addressed for minimal impact.
Opportunities lie in continued cost reductions, growth normalization, and operational improvements.
Overall, Cardinal Health is well-positioned to navigate challenges and capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Chubb

Diageo

GlaxoSmithKline

Illinois Tool Works

Johnson Controls

Kimberly-Clark

Coca-Cola

Leggett & Platt

Mondelez

Altria

Philip Morris

Without rehashing the wild ride we experienced in the market the last couple of months with triple digit gains and losses, I could find comfort in one thing, my dividends. Dividends may not increase every year and a cut or elimination is even possible, but the odds are greatly reduced when you diversify among different companies and sectors and focus on dividend quality. Another four-digit month came in this year. As you can imagine, I am quite happy seeing that.

Dividend Income Update October 2023

American Eagle Outfitters

Abercrombie & Fitch

Runway Growth Finance Corp

With things looking up for the stock market this November, investing in growth stocks such as American Eagle Outfitters (AEO), Abercrombie & Fitch (ANF), Cardinal Health (CAH) and Runway Growth Finance (RWAY) seems prudent.

4 Growth Stocks to Take Advantage of the November Rally

Nucor

Exxon Mobil

There is no substitute for dividend stocks when it comes to making money on Wall Street. Time and again studies show dividend payers significantly outperform those that do not.

Royal Rule: Buy These 3 Dividend Aristocrats on Every. Single. Dip.

Cardinal Health's (CAH) SmartGown EDGE Breathable Surgical Gown will enable clinical teams to focus on delivering safe patient care by reducing instrument handoffs and contamination.

Cardinal Health (CAH) Launches Surgical Gown for Safe Surgery

SmartGown™ EDGE is the first pocketed surgical gown designed to help maintain instrument sterility and accessibility. DUBLIN, Ohio , Nov. 9, 2023 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today the U.S. launch of its SmartGown™ EDGE Breathable Surgical Gown with ASSIST™ Instrument Pockets, created to provide surgical teams safe and convenient instrument access in the operating room.

Cardinal Health launches SmartGown™ EDGE Breathable Surgical Gown with ASSIST™ Instrument Pockets

NetEase

Ferrari

These leading stocks hit new highs and broke out of bases as the market reignited on Friday.

These Leading Stocks Reach New Highs As The Market Awakens

Cardinal Health, Inc. (NYSE:CAH ) Q1 2024 Earnings Conference Call November 3, 2023 8:30 AM ET Company Participants Matt Sims - VP of IR Jason Hollar - CEO Aaron Alt - CFO Conference Call Participants Lisa Gill - JPMorgan Eric Percher - Nephron Research Kevin Caliendo - UBS Erin Wright - Morgan Stanley George Hill - Deutsche Bank Elizabeth Anderson - Evercore Daniel Grosslight - Citi Charles Rhyee - TD Cowen Allen Lutz - Bank of America Operator Good day, and welcome to today's First Quarter Financial Year 2024 Cardinal Health Earnings Conference Call. This meeting is being recorded.

Cardinal Health, Inc. (CAH) Q1 2024 Earnings Call Transcript

Cardinal Health's (CAH) first-quarter fiscal 2024 results benefit from the Pharmaceutical segment's solid performance.

Cardinal Health (CAH) Beats on Q1 Earnings, Ups '24 EPS View

While the top- and bottom-line numbers for Cardinal (CAH) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Cardinal (CAH) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Cardinal Health (CAH) came out with quarterly earnings of $1.73 per share, beating the Zacks Consensus Estimate of $1.40 per share. This compares to earnings of $1.20 per share a year ago.

Cardinal Health (CAH) Surpasses Q1 Earnings and Revenue Estimates

Shares of Cardinal Health Inc. CAH, +0.21% climbed 1.3% into record territory in premarket trading Friday, after the drug distributor reported fiscal first-quarter profit that beat expectations and raised its full-year outlook, while revenue came up a bit shy. Net income for the quarter to Sept.

Cardinal Health's stock rises into record territory after profit beat, raised outlook

Revenue increased 10% to $54.8 billion GAAP 1 operating loss was $14 million and GAAP diluted EPS was $0.02, driven by a Medical segment goodwill impairment Non-GAAP operating earnings increased 35% to $571 million, driven by significant increases in both Pharmaceutical segment profit and Medical segment profit; non-GAAP diluted EPS increased 44% to $1.73 Pharmaceutical segment profit grew 18% to $507 million and the Medical segment delivered $71 million in segment profit Fiscal 2024 non-GAAP EPS guidance raised to $6.75 to $7.00, from $6.50 to $6.75 DUBLIN, Ohio , Nov. 3, 2023  /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported first quarter fiscal 2024 revenue of $54.8 billion, an increase of 10% from the first quarter of last year. First quarter GAAP operating loss was $14 million due to a non-cash, pre-tax goodwill impairment of $581 million related to the Medical segment, due to an increase in the discount rate.

Cardinal Health Reports First Quarter Fiscal 2024 Results and Raises Fiscal 2024 Outlook

AbbVie

Abbott Labs

Archer-Daniels-Midland Company

Automatic Data Processing

Aflac

Albemarle

Amcor Plc

A. O. Smith

Air Products and Chemicals

Atmos Energy

Becton, Dickinson and Co.

Franklin Resources

Brown & Brown

Caterpillar

Cincinnati Financial

Colgate-Palmolive

Clorox

Cintas Corp

Chevron

Dover

Ecolab

Con Ed

Emerson Electric

Essex Property Trust

Expeditors International of Washington

Federal Realty Investment Trust

General Dynamics

Genuine Parts

W.W. Grainger

Hormel Foods

Johnson & Johnson

New Linde PLC

Lowe's

McDonald's

Medtronic

McCormick

Nordson

NextEra Energy

Realty Income Corp

PepsiCo

Procter & Gamble

Pentair

PPG Industries

Roper Technologies

Sherwin-Williams

S&P Global

Stanley Black & Decker

Sysco

Target

T. Rowe Price Group

V.F.

Walgreens

Walmart

West Pharmaceutical Services

The highest yield isn't everything when it comes to finding the best dividend stocks. Income investors know there's no substitute for regular dividend increases over the long haul.

67 Best Dividend Stocks for Dependable Dividend Growth

News for Cardinal Health Stock (CAH)